67571-10-2

Upstream product

• 619-17-0 4-Nitroanthranilic acid 
• 63480-10-4 4-nitroisatoic anhydride 
• 100-63-0 phenylhydrazine 

Downstream Products

• 1254069-40-3 3-(methylthio)-6-nitro-1-phenyl-1H-indazole 
• 1254069-38-9 3-(methylthio)-1-phenyl-1H-indazol-6-amine 
• 1254069-41-4 4-(3-methylsulfanyl-1-phenyl-1H-indazol-6-ylcarbamoyl)piperidine-1-carboxylicacid tert-butyl ester 
• 1254069-36-7 N-(3-(methylthio)-1-phenyl-1H-indazol-6-yl)piperidine-4-carboxamide hydrochloride 
• 1254069-39-0 6-nitro-1-phenyl-2,3-dihydro-1H-indazol-3-one 
• 1254069-37-8 6-nitro-1-phenyl-1,2-dihydroindazol-3-thione 
• 1345404-93-4 3-methoxy-1-phenyl-1H-indazol-6-ylamine 
• 1345404-92-3 3-methoxy-6-nitro-1-phenyl-1H-indazole 
• 1345404-02-5 3-[3-(3-Methylsulfanyl-1-phenyl-1H-indazol-6-yl)-ureido]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1345404-00-3 2-[(3-Methylsulfanyl-1-phenyl-1H-indazol-6-ylcarbamoyl)-methyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1345403-98-6 3-(3-Methylsulfanyl-1-phenyl-1H-indazol-6-ylcarbamoyl)-azetidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Electron density guided fragment-based lead discovery of ketohexokinase inhibitors

A fragment-based drug design paradigm has been successfully applied in the discovery of lead series of ketohexokinase inhibitors. The paradigm consists of three iterations of design, synthesis, and X-ray crystallographic screening to progress low molecula

INDAZOLE COMPOUNDS USEFUL AS KETOHEXOKINASE INHIBITORS

The present invention is directed to substituted indazole compounds, pharmaceutical compositions of these compounds and methods of use thereof. The compounds of the present invention are ketohexokinase (KHK) inhibitors, useful for treating or ameliorating a KHK mediated metabolic disorders and/or diseases such as obesity, Type II diabetes mellitus and Metabolic Syndrome X.